Chiesi USA, Inc.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Activity

Recent Activity

Last 14 days

Oct 29, 2026

Completed

Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Earlier

Mar 26, 2025FDAFerriprox — FERRIPROX

Jan 26, 2023FDAKengreal — KENGREAL

Nov 30, 2021FDAFerriprox — FERRIPROX

1 more events

Apr 30, 2021FDAFerriprox — FERRIPROX

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

7 patent groups across drugs · Source: FDA Orange Book

DrugExpires

KengrealMay 13, 2029 FerriproxOct 26, 2029 KengrealNov 10, 2030 Cleviprex3 patentsOct 10, 2031 KengrealMar 9, 2033 Kengreal4 patentsJul 10, 2035 Ferriprox6 patentsOct 25, 2038

Regulatory

Regulatory Timeline

20151 event

FDASep 9

Ferriprox — FERRIPROX

Application NDA208030

20161 event

FDAMar 2

Kengreal — KENGREAL

Application NDA204958

20182 events

FDAApr 20

Ferriprox — FERRIPROX

Application NDA208030 (NDA)

FDAApr 20

Ferriprox — FERRIPROX

Application NDA208030

20193 events

FDAOct 23

Kengreal — KENGREAL

Application NDA204958

FDAJul 25

Ferriprox — FERRIPROX

Application NDA021825 (NDA)

FDAJul 25

Ferriprox — FERRIPROX

Application NDA021825

20203 events

FDAMay 19

Ferriprox — FERRIPROX

Application NDA212269 (NDA)

FDAFeb 20

Ferriprox — FERRIPROX

Application NDA021825

FDAFeb 20

Ferriprox — FERRIPROX

Application NDA208030

20216 events

FDANov 30

Ferriprox — FERRIPROX

Application NDA021825

FDANov 30

Ferriprox — FERRIPROX

Application NDA208030

FDANov 30

Ferriprox — FERRIPROX

Application NDA212269

FDAApr 30

Ferriprox — FERRIPROX

Application NDA212269

FDAApr 30

Ferriprox — FERRIPROX

Application NDA021825

FDAApr 30

Ferriprox — FERRIPROX

Application NDA208030

20231 event

FDAJan 26

Kengreal — KENGREAL

Application NDA204958

20253 events

FDAMar 26

Ferriprox — FERRIPROX

Application NDA021825

FDAMar 26

Ferriprox — FERRIPROX

Application NDA212269

FDAMar 26

Ferriprox — FERRIPROX

Application NDA208030

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)